Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

6.670 -0.070 (-1.04%)

Streaming Delayed Price Updated: 9:41 AM EDT, Aug 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	5,148
Open	6.660
Bid (Size)	6.650 (100)
Ask (Size)	6.710 (100)
Prev. Close	6.740
Today's Range	6.660 - 6.690
52wk Range	5.140 - 10.42
Shares Outstanding	37,953,711
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

DiaMedica (DMAC) Q2 2026 Earnings Call Transcript ↗

August 17, 2026

ReMEDy2 stroke trial nears interim analysis with 85% enrollment complete.

Via The Motley Fool

DiaMedica Therapeutics Q2 Earnings Call Highlights ↗

August 11, 2026

DiaMedica Therapeutics (NASDAQ:DMAC) said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the...

Via MarketBeat

Performance

YTD	-15.9%	-15.9%
1 Month	-1.0%	-1.0%
3 Month	+5.5%	+5.5%
6 Month	-22.0%	-22.0%
1 Year	+11.2%	+11.2%

More News

DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

August 10, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics (NASDAQ:DMAC) Posts Wider Q1 Loss but Clinical Catalysts Fuel Stock Resilience ↗

May 06, 2026

Via Chartmill

DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026

August 04, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

June 23, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program

June 16, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica (DMAC) Q4 2025 Earnings Transcript ↗

June 01, 2026

Via The Motley Fool

DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026

May 27, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

May 20, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

May 12, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica (DMAC) Q1 2026 Earnings Transcript ↗

May 08, 2026

Via The Motley Fool

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

May 06, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

April 30, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

RedChip's Biotech Virtual Investor Conference Replays Now Available

April 21, 2026

Via ACCESS Newswire

RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms

April 07, 2026

Via ACCESS Newswire

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

March 30, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings ↗

March 30, 2026

Via Benzinga

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026

March 23, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

March 05, 2026

From DiaMedica Therapeutics Inc

Via Business Wire

DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

February 24, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA

December 18, 2025

From DiaMedica Therapeutics Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

November 14, 2025

Via Benzinga

Frequently Asked Questions

Is DiaMedica Therapeutics Inc. - Common Stock publicly traded?

Yes, DiaMedica Therapeutics Inc. - Common Stock is publicly traded.

What exchange does DiaMedica Therapeutics Inc. - Common Stock trade on?

DiaMedica Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for DiaMedica Therapeutics Inc. - Common Stock?

The ticker symbol for DiaMedica Therapeutics Inc. - Common Stock is DMAC on the Nasdaq Stock Market

What is the current price of DiaMedica Therapeutics Inc. - Common Stock?

The current price of DiaMedica Therapeutics Inc. - Common Stock is 6.670

When was DiaMedica Therapeutics Inc. - Common Stock last traded?

The last trade of DiaMedica Therapeutics Inc. - Common Stock was at 08/26/26 09:41 AM ET

What is the market capitalization of DiaMedica Therapeutics Inc. - Common Stock?

The market capitalization of DiaMedica Therapeutics Inc. - Common Stock is 253.15M

How many shares of DiaMedica Therapeutics Inc. - Common Stock are outstanding?

DiaMedica Therapeutics Inc. - Common Stock has 253M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.